Leiomyosarcoma is a rare entity in prostate but it is the most common type of prostate sarcomas in adult patients. In most reported series the prognosis is poor and the median survival is about 15-18 months. Hereby we present a 72 years old man who received combined modality treatment including radical surgery followed by adjuvant chemotherapy and radiotherapy. He has been well for 14 months, b...

BACKGROUND Hypo-fractionated external beam radiotherapy with narrow CTV-PTV margins is increasingly applied for prostate cancer. This demands a precise target definition and knowledge on target location and extension during treatment. It is unclear how increase in fraction size affects changes in prostate volume during treatment. Our aim was to study prostate volume changes during extreme hypo-...

OBJECTIVE To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut. DESIGN Natural experiment comparing two fixed cohorts from 1987 to 1997. SETTING Seattle-Puget Sound and Connecticut surveillance, epidemiology, and end results areas. PARTICIPANTS Populati...

Tremendous technological advancements in prostate radiotherapy have decreased treatment toxicity and improved clinical outcomes for men with prostate cancer. While these advances have allowed for significant treatment volume reduction and whole-organ dose escalation, further improvement in prostate radiotherapy has been limited by classic techniques for diagnosis and risk stratification. Develo...

OBJECTIVES Salvage radiotherapy is the only curative treatment for patients with prostate cancer showing biochemical progression after radical prostatectomy. In this study, we evaluated the clinicopathological parameters that influence the outcome of salvage radiotherapy. METHODS Medical records of 49 patients who underwent salvage radiotherapy after radical prostatectomy from 1997 to 2008 at...

Prostate cancer is the most common male cancer with an annual incidence of 36,000 cases in the UK [301]. Management of these patients includes surveillance and radical treatment with either surgery or radiotherapy. Active surveillance of prostate cancer is a possible management strategy for men with low-risk disease, avoiding treatment-related morbidity but requiring a robust follow-up strategy...

The public reporting of patient outcomes is crucial for quality improvement and informing choice. However, outcome in radiotherapy, despite being a major component cancer control, extremely sparse globally. Public has many challenges, including difficulties defining meaningful measures treatment quality, limitations data infrastructure, fragmented health insurance schemes. National Prostate Can...

Background: Radiation therapy is among the most conventional cancer therapeutic modalities with effective local tumor control. However, due to the development of radio-resistance, tumor recurrence and metastasis often occur following radiation therapy. In recent years, combination of radiotherapy and gene therapy has been suggested to overcome this problem. The aim of the current study was to e...

BACKGROUND Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP) trial. METHODS The...

OBJECTIVES The treatment of recurrent prostate cancer after radiotherapy or brachytherapy through radical prostatectomy has been little indicated due to the concern over the procedure's morbidity. We present the experience of our service with postradiotherapy radical prostatectomy. MATERIALS AND METHODS Between 1996 and 2002, 9 patients submitted to radiotherapy due to prostate cancer were tr...